Physician profile

Peter V Wilson

Surgery · Layton, UT

NPI 1518998921

$223.51

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$40.05

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $40.05 2023 Da Vinci Surgical System
Covidien LP $36.28 2019
Astrazeneca Pharmaceuticals LP $34.76 2021
Merit Medical Systems INC $22.22 2021
Portola Pharmaceuticals, LLC $17.51 2019
Takeda Pharmaceuticals U.S.A., INC. $15.64 2020
Boston Scientific Corporation $15.37 2021
Teleflex LLC $15.29 2021
Acell, INC. $14.27 2020
Braintree Laboratories, INC. $12.12 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Peter V Wilson

$223.51

in general payments reported 2019-2025

Years
2019-2023
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/805200/peter-v-wilson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.